Researchers at McGill University have reported that lithium, a long-established treatment for bipolar disorder, suppressed ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

In a randomized trial, ART intensification by doubling the dolutegravir dosage in people with HIV stably suppressed on ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...

In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...

A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some HIV-positive individuals, known as viremic non-progressors (VNPs), to avoid ...

Godfrey Dzhivhuho has dedicated his career to understanding HIV and other infectious diseases, inspired by the epidemic he witnessed growing up. Raised in Warrenton-Kimberly, South Africa, the oldest ...

HIV-1 infection, in combination with other antiretrovirals, in treatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals. Raltegravir ...

CD8 T lymphocytes from immunologically stable HIV-1-infected secrete a soluble factor — termed CAF —, which suppresses HIV-1 replication, but the exact identity of CAF has been unclear. In September ...